Plant Name: Pteris australis
Taxonomic Information:
Plant ID: NPO10396
Plant Latin Name: Pteris australis
Taxonomy Genus: Pteris
Taxonomy Family: Pteridaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| RECQL; TDP1; AKR1B1; HSD17B2; HPGD; APEX1; POLB; | |
| TEK; INSR; MET; KDR; EGFR; SRC; IGF1R; CSNK2A1; NUAK1; | |
| CA12; CA7; | |
| TYR; | |
| AHR; | |
| SLC22A6; SLCO1B3; | |
| SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 3.826E-10 | 2.083E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.787E-09 | 1.541E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.556E-08 | 4.076E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.540E-07 | 1.620E-04 | EGFR, INSR, KDR |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.261E-07 | 1.732E-04 | AKR1B1, APEX1, CSNK2A1, CYP1A2, EGFR, HPGD, INSR, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 1.865E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.849E-07 | 2.497E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.235E-06 | 4.137E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.333E-06 | 4.399E-04 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.176E-06 | 6.404E-04 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.869E-06 | 8.041E-04 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.880E-06 | 8.041E-04 | EGFR, INSR, MET, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.974E-06 | 1.055E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.793E-06 | 1.200E-03 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.281E-06 | 1.307E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.523E-06 | 1.439E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 7.015E-06 | 1.489E-03 | EGFR, IGF1R, INSR, KDR, MET, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 7.830E-06 | 1.579E-03 | CSNK2A1, CYP1A1, CYP1A2, EGFR, HPGD, HSD17B2, SRC, TYR |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.722E-06 | 1.579E-03 | EGFR, HPGD, SLC22A6, SLCO1B3, TEK |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.014E-05 | 1.989E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, EGFR, HSPA1A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.303E-05 | 2.365E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.303E-05 | 2.365E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.328E-05 | 2.373E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.466E-05 | 2.573E-03 | AHR, CSNK2A1, KDR |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.170E-05 | 3.425E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 2.918E-05 | 4.352E-03 | EGFR, INSR, KDR, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 3.121E-05 | 4.531E-03 | EGFR, INSR, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.252E-05 | 4.569E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.252E-05 | 4.569E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 4.549E-05 | 5.793E-03 | CYP1A2, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 4.549E-05 | 5.793E-03 | EGFR, POLB |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.535E-05 | 6.848E-03 | AKR1B1, CA12, CA7, EGFR, GPR35, INSR, MET, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 6.060E-05 | 7.455E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 7.574E-05 | 8.819E-03 | EGFR, IGF1R, INSR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.117E-18 | 3.429E-16 | CA12, CA2, CA5A, CA4, CA7, CA6, CA9, CA14, CA13 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.736E-11 | 9.374E-10 | PDGFRB, GSK3B, SMAD3, FLT3, DAPK1, BRAF, HIF1A, EGFR, PTK2, IGF1R, AR, ERBB2, AKT1, MET, TP53 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.215E-11 | 9.374E-10 | PDGFRB, GSK3B, SRC, FLT4, ERBB2, KDR, AKT1, BRAF, MET, PTK2, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 4.467E-11 | 1.809E-09 | PDGFRB, GSK3B, AR, ERBB2, AKT1, BRAF, TP53, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.494E-10 | 6.734E-09 | SRC, ERBB2, KDR, AKT1, BRAF, TP53, HIF1A, MET, PTK2, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.455E-10 | 4.715E-09 | PDGFRB, FLT3, ERBB2, AKT1, TP53, MET, HIF1A, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 3.767E-10 | 7.627E-09 | PDGFRB, SRC, INSR, FLT4, KDR, AKT1, BRAF, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.293E-10 | 7.622E-09 | SMAD3, CSNK2A1, SRC, INSR, ERBB2, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.965E-09 | 8.043E-08 | PDGFRB, GSK3B, INSR, FLT4, KDR, AKT1, TEK, TP53, MET, PTK2, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.875E-10 | 1.237E-08 | HSD17B1, ALOX5, INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.598E-09 | 1.241E-07 | PDGFRB, AKT1, BRAF, TP53, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.590E-08 | 4.168E-07 | PLK4, SMAD3, INSR, PLK1, AKT1, BRAF, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 3.602E-08 | 4.168E-07 | GSK3B, SRC, ERBB2, AKT1, BRAF, EGFR, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.190E-09 | 1.241E-07 | DAPK1, SRC, ERBB2, BRAF, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 4.028E-08 | 4.350E-07 | GSK3B, ERBB2, AKT1, BRAF, TP53, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.749E-07 | 1.349E-06 | PDGFRB, INSR, FLT4, KDR, AKT1, TEK, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.572E-07 | 1.341E-06 | PDGFRB, AKT1, BRAF, TP53, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.164E-07 | 1.048E-06 | INSR, ERBB2, AKT1, TEK, HIF1A, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.725E-07 | 1.349E-06 | SMAD3, ERBB2, AKT1, BRAF, TP53, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.866E-08 | 7.496E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 5.051E-06 | 3.273E-05 | PDGFRB, DUSP3, AKT1, BRAF, MAP3K8, TP53, EGFR, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.131E-06 | 1.501E-05 | ERBB2, AKT1, BRAF, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.339E-07 | 4.668E-06 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 3.548E-06 | 2.395E-05 | GSK3B, SMAD3, AKT1, BRAF, TP53 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 5.280E-05 | 3.055E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.169E-08 | 7.259E-07 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.976E-06 | 4.786E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 6.954E-06 | 4.333E-05 | SLCO1B1, CA2, SLCO1B3, CYP3A4, ABCG2 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.885E-05 | 3.287E-04 | HPGD, FLT3, TP53, MET, PTK2, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.359E-05 | 3.434E-04 | CYP2C9, ALOX5, ALOX15, BRAF, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 8.151E-05 | 4.126E-04 | GSK3B, SRC, AKT1, TP53, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.242E-04 | 5.440E-04 | PDGFRB, ABCC1, ERBB2, CYP1B1, TP53, MET, EGFR |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.817E-04 | 6.847E-04 | GAA, ALOX15, AKR1B1, CYP2C19, CYP3A4, TYR, HSD17B10, CYP2C9, HSD17B1, ALOX5, HSD17B2, CYP1A2, CYP1A1, XDH |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 8.096E-05 | 4.126E-04 | SRC, KDR, AKT1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.591E-04 | 6.287E-04 | GSK3B, CSNK2A1, AKT1, TP53, HSPA1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.433E-04 | 5.805E-04 | GSK3B, AKT1, BRAF, TP53, EGFR |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 9.773E-05 | 4.657E-04 | INSR, AKT1, HSPA1A, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 4.160E-04 | 1.532E-03 | PDGFRB, POLB, GSK3B, SMAD3, AKT1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 8.629E-05 | 4.236E-04 | CYP2C9, ALOX5, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.102E-04 | 4.961E-04 | AKT1, BRAF, MET, HIF1A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 4.793E-04 | 1.652E-03 | PDGFRB, FLT3, FLT4, KDR, MET, EGFR |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.038E-04 | 4.807E-04 | CYP2C9, CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.632E-04 | 6.295E-04 | SMAD3, AKT1, BRAF, TP53 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 4.309E-04 | 1.551E-03 | INSR, AKT1, TP53, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.311E-04 | 5.589E-04 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 9.735E-04 | 3.033E-03 | GSK3B, CSNK2A1, AKT1, TP53, HSPA1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 5.047E-04 | 1.703E-03 | PLK1, AKT1, BRAF, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 6.885E-04 | 2.187E-03 | GSK3B, SRC, AKT1, BRAF, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.245E-04 | 1.734E-03 | SRC, AKT1, EGFR, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 5.657E-04 | 1.833E-03 | PDGFRB, AKT1, HIF1A, EGFR |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 1.258E-03 | 3.640E-03 | PDGFRB, SRC, BRAF, PTK2, EGFR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.079E-03 | 3.297E-03 | GSK3B, AKT1, BRAF, TP53 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.182E-03 | 3.546E-03 | AR, PLK1, AURKA, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.218E-03 | 3.588E-03 | GSK3B, SMAD3, PLK1, TP53 |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 1.331E-03 | 3.717E-03 | GSK3B, MET, PTK2, EPHB4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.004E-03 | 5.236E-03 | GSK3B, SMAD3, AKT1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 2.004E-03 | 5.236E-03 | GSK3B, SMAD3, CSNK2A1, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 1.854E-03 | 5.005E-03 | GSK3B, INSR, AKT1, BRAF |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 2.109E-03 | 5.394E-03 | PDGFRB, INSR, AKT1, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.217E-03 | 5.525E-03 | SMAD3, SRC, AKT1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 4.147E-03 | 9.737E-03 | AKT1, TP53, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.509E-03 | 6.158E-03 | GSK3B, SRC, AKT1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.487E-03 | 4.082E-03 | AKT1, BRAF, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 3.149E-03 | 7.615E-03 | SRC, MET, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.281E-03 | 3.642E-03 | FLT3, AKT1, BRAF |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.131E-03 | 5.394E-03 | SRC, MET, EGFR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.529E-04 | 1.595E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 3.336E-03 | 7.947E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.377E-04 | 5.722E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | HIV infections | NA | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; TEK; EGFR; SRC; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
